

International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names (Rec. INN): List 37

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy. Lists of Proposed (1–73) and Recommended (1–35) International Nonproprietary Names can be found in *Cumulative List No. 9, 1996*.

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMANDÉES (DCI Rec): Liste 37

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9)] les dénominations ci-dessous sont mises à l'étude par l'Organisation mondiale de la Santé en tant que dénominations communes internationales proposées. L'inclusion d'une dénomination dans les listes de DCI proposées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie. On trouvera d'autres listes de Dénominations communes internationales proposées (1–73) et recommandées (1–35) dans la *Liste récapitulative No. 9, 1996*.

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales RECOMENDADAS (DCI Rec.): Lista 37

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia. Las listas de Denominaciones Comunes Internacionales Propuestas (1–73) y Recomendadas (1–35) se encuentran reunidas en *Cumulative List No. 9, 1996*.

MODIFICATION

This is to inform you that WHO will henceforth publish lists of recommended INNs **twice a year**.

This new measure is intended to provide information as soon as possible on the names that have reached the status of recommended INNs.

MODIFICATION

L'OMS publiera désormais les listes des DCI recommandées **deux fois par an**.

Cette nouvelle mesure est destinée à informer les lecteurs dès que possible au sujet des dénominations ayant atteint le statut de DCI recommandée.

MODIFICACION

De ahora en adelante, la OMS publicará **dos veces por año** las listas de DCI recomendadas.

Con esta nueva medida se quiere facilitar lo antes posible la información sobre las denominaciones a las que se ha asignado la condición de DCI recomendadas.

Latin, English, French, Spanish:*Recommended INN**Chemical name or description; Molecular formula; Graphic formula**DCI Recommandée**Nom chimique ou description; Formule brute; Formule développée**DCI Recomendada**Nombre químico o descripción; Fórmula empírica; Fórmula desarrollada***agomelatinum**


agomelatine

N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide

agomélatine

N-[2-(7-méthoxynaphtalén-1-yl)éthyl]acétamide

agomelatina

N-[2-(7-metoxi-1-naftil)etil]acetamidaC₁₅H₁₇NO₂**alatrofloxacinum**


alatrofloxacin

7-[(1*R*,5*S*,6*s*)-6-[(*S*)-2-[(*S*)-2-aminopropionamido]propionamido]-3-azabicyclo[3.1.0]hex-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid

alatrofloxacine

acide 7-[(1*R*,5*S*,6*s*)-6-[[2*S*)-2-[[2*S*)-2-aminopropanoyl]amino]propanoyl]=amino]-3-azabicyclo[3.1.0]hex-3-yl]-1-(2,4-difluorophényl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylique

alatrofloxacino

ácido 7-[(1*R*,5*S*,6*s*)-6-[(*S*)-2-[(*S*)-2-aminopropionamido]propionamido]-3-azabicyclo[3.1.0]hex-3-il]-1-(2,4-difluorofenil)-6-fluoro-1,4-dihidro-4-oxo-1,8-naftiridina-3-carboxílicoC₂₆H₂₅F₃N₆O₅

aripiprazolum

aripiprazole


7-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydrocarbostyryl

aripiprazole

7-[4-[4-(2,3-dichlorophényl)pipérazin-1-yl]butoxy]-3,4-dihydroquinoléin-2(1*H*)-one

aripiprazol

7-[4-[4-(2,3-diclorofenil)-1-piperazinil]butoxi]-3,4-dihidrocarbostiril

 $C_{23}H_{27}Cl_2N_3O_2$ **arofyllinum**


arofylline

3-(*p*-chlorophenyl)-1-propylxanthine

arofylline

3-(4-chlorophényl)-1-propyl-3,7-dihydro-1*H*-purine-2,6-dione

arofilina

3-(*p*-clorofenil)-1-propilxantina $C_{14}H_{13}ClN_4O_2$ **atiprimodum**

atiprimod


2-[3-(diethylamino)propyl]-8,8-dipropyl-2-azaspiro[4.5]decane

atiprimod

3-[8,8-dipropyl-2-azaspiro[4.5]déc-2-yl]-*N,N*-diéthylpropan-1-amine

atiprimod

2-[3-(diethylamino)propil]-8,8-dipropil-2-azaspiro[4.5]decano

 $C_{22}H_{44}N_2$ 

bectumomabum

bectumomab

immunoglobulin G 2a (mouse monoclonal IMMU-LL2 Fab' fragment γ -chain anti-human antigen CD 22), disulfide with mouse monoclonal IMMU-LL2 light chain

bectumomab

immunoglobuline G 2a (chaîne γ du fragment Fab' de l'anticorps monoclonal de souris IMMU-LL2 anti-antigène CD 22 humain), disulfure avec la chaîne légère de l'anticorps monoclonal de souris IMMU-LL2

bectumomab

immunoglobulina G 2a (cadena γ del fragmento Fab' del anticuerpo monoclonal de ratón IMMU-LL2 anti-antígeno CD 22 humano), disulfuro con la cadena ligera del anticuerpo monoclonal de ratón IMMU-LL2

beloxepinum

beloxepin


(\pm)-*cis*-1,3,4,13b-tetrahydro-2,10-dimethyldibenz[2,3:6,7]oxepino=[4,5-*c*]pyridin-4a(2*H*)-ol

béloxépine

(4*aRS*,13*bRS*)-2,10-diméthyl-1,3,4,13b-tétrahydrodibenzo[2,3:6,7]oxépino=[4,5-*c*]pyridin-4a(2*H*)-ol

beloxepina

(\pm)-*cis*-1,3,4,13b-tetrahydro-2,10-dimetildibenz[2,3:6,7]oxepino=[4,5-*c*]piridin-4a(2*H*)-ol

C₁₉H₂₁NO₂

and enantiomer
et l'énantiomère
y enantiómero

bemiparinum natricum

bemiparin sodium

Sodium salt of depolymerized heparin obtained by alkaline degradation of quaternary ammonium salt of heparin from pork intestinal mucosa; the majority of the components have a 2-*O*-sulfo-4-eneopyranosuronic acid structure at the non-reducing end and a 2-*N*,6-*O*-disulfo- β -glucosamine structure at the reducing end of their chain; the average relative molecular mass is about 3600 (3000 to 4200); the degree of sulfatation is about 2 per disaccharidic unit.

bémparine sodique

Sel de sodium d'héparine dépolymérisée obtenue par fragmentation alcaline d'un sel d'ammonium quaternaire d'héparine de muqueuse intestinale de porc. La majorité des composants présentent une structure acide 2-*O*-sulfo-4-èneopyranosuronique à l'extrémité non réductrice et une structure 2-*N*,6-*O*-disulfo- β -glucosamine à l'extrémité réductrice de leur chaîne. La masse moléculaire relative moyenne est voisine de 3600 (3000 à 4200). Le degré de sulfatation est voisin de 2 par unité disaccharide.

bemiparina sódica

Sal de sodio de heparina despolimerizada obtenida por fragmentación alcalina de una sal de amonio cuaternario de heparina de mucosa intestinal de cerdo. La mayoría de los componentes presentan una estructura ácido 2-O-sulfo-4-enopiranosurónico en el extremo no reductor y una estructura 2-N,6-O-disulfo-D-glucosamina en el extremo reductor de su cadena. La masa molecular relativa media es aproximadamente 3600 (de 3000 a 4200). El grado de sulfatación es aproximadamente 2 por unidad de disacárido.

cemadotinum


cemadotin

N,N-dimethyl-L-valyl-L-valyl-*N*-methyl-L-valyl-L-prolyl-*N*-benzyl-L-prolinamide

cémadotine

(N,N-diméthyl-L-valyl)-L-valyl-*(N*-méthyl-L-valyl)-L-prolyl-*(N*-benzyl-L-prolinamide)

cemadotina

N,N-dimetil-L-valil-L-valil-*N*-metil-L-valil-L-prolil-*N*-bencil-L-prolinamidaC₃₅H₅₆N₆O₅**choriogonadotropinum alfa**

choriogonadotropin alfa

human chorionic gonadotropin (protein moiety reduced), glycoform α -subunit:chorionic gonadotropin (human α -subunit protein moiety reduced) β -subunit:chorionic gonadotropin (human β -subunit protein moiety reduced)

choriogonadotropine alfa

gonadotropine chorionique humaine (partie protéique réduite), forme glycosylée α sous-unité α :gonadotropine chorionique (partie protéique réduite de la sous-unité α humaine)sous-unité β :gonadotropine chorionique (partie protéique réduite de la sous-unité β humaine)

coriogonadotropina alfa

gonadotropina coriónica humana (fracción proteica reducida), glucoforma α subunidad α :gonadotropina coriónica (fracción proteica reducida de la subunidad α humana)subunidad β :gonadotropina coriónica (fracción proteica reducida de la subunidad β humana) α : C₄₃₇H₆₈₂N₁₂₂O₁₃₄S₁₃ β : C₆₆₈H₁₀₉₀N₁₉₆O₂₀₃S₁₃

APDVQDCPEC TLQENPFFSQ PGAPILQCMG CCFSTRAYPTP
 LRSKKTMLVQ KNVTSSESTCC VAKSYNRVTV MGGFKVENHT
 AHCSTCYHYH KS
 SKEPLRPRCR PINATLAVEK EGCPVCITVN TTICAGYCPT
 MTRVLQGVLP ALPQVVCNYR DVRFESIRLP GCPRGVNPVV
 SYAVALSCQC ALCRRSTTDC GGPKDHPLTC DDPRFQDSSS
 SKAPPPSLPS PSRLPGPSDT PILPQ

clevidipinum

clevidipine


(±)-hydroxymethyl methyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate, butyrate (ester)

clévidipine

(4*RS*)-4-(2,3-dichlorophényl)-2,6-diméthyl-1,4-dihydropyridine-3,5-dicarboxylate de butanoyloxyméthyle et de méthyle

clevidipino

(±)-4-(2,3-diclorofenil)-1,4-dihidro-2,6-dimetil-3,5-píridinadicarboxilato de butiriloximetilo y metilo

 $C_{21}H_{23}Cl_2NO_6$
**domitrobanum**

domitroban


(+)-(Z)-7-[(1*R*,2*S*,3*S*,4*S*)-3-benzenesulfonamido-2-norbornyl]-5-heptenoic acid

domitroban

acide (+)-(Z)-7-[(1*R*,2*S*,3*S*,4*S*)-3-[(phénylsulfonyl)amino]bicyclo[2.2.1]hept-2-yl]hept-5-énoïque

domitrobán

ácido (+)-(Z)-7-[(1*R*,2*S*,3*S*,4*S*)-3-bencensulfonamido-2-norbornil]-5-heptenoico

 $C_{20}H_{27}NO_4S$


donepezilum


donepezil

 (\pm) -2-[(1-benzyl-4-piperidyl)methyl]-5,6-dimethoxy-1-indanone

donépézil

 $(2RS)$ -2-[(1-benzylpipéridin-4-yl)méthyl]-5,6-diméthoxy-2,3-dihydro-1*H*-indén-1-one

donepezilo

 (\pm) -2-[(1-bencil-4-piperidil)metil]-5,6-dimetoxi-1-indanona $C_{24}H_{29}NO_3$ **dronedaronum**


dronedarone

N-[2-butyl-3-*p*-[3-(dibutylamino)propoxy]benzoyl]-5-benzofuranyl]=methanesulfonamide

dronédarone

N-[2-butyl-3-[4-[3-(dibutylamino)propoxy]benzoyl]benzofuran-5-yl]méthanesulfonamide

dronedarona

N-(2-butil-3-[*p*-[3-(dibutilamino)propoxi]benzoil]-5-benzofuranil)=metanosulfonamida $C_{31}H_{44}N_2O_5S$ **ecamsulum**


ecamsule

 (\pm) -(3*E*,3'*E*)-3,3'-(*p*-phenylenedimethylidene)bis[2-oxo-10-bornanesulfonic acid]

écamsule

acide [[1,4-phénylènediméthylidyne]bis[(3*E*,3'*E*)-7,7-diméthyl-2-oxobicyclo[2.2.1]heptan-3,1-diyl]]diméthanesulfonique

ecamsul

 (\pm) -(3*E*,3'*E*)-3,3'-(*p*-fenilenodimetilidino)bis[ácido 2-oxo-10-bornanosulfónico] $C_{28}H_{34}O_8S_2$ 

efepristinum

efepristin


N-[(6*R*,9*S*,10*R*,13*S*,15*aS*,22*S*,24*aS*)-6-ethyl-10,23-diméthyl-22-[*p*-(méthylamino)benzyl]-5,8,12,15,17,21,24-hepta-oxo-13-phényl-12*H*-pyrido[2,1-*f*]pyrrolo[2,1-*h*][1,4,7,10,13,16]oxapentaazacyclononadecin-9-yl]-3-hydroxypicolinamide

éfépristine

N-[(6*R*,9*S*,10*R*,13*S*,15*aS*,22*S*,24*aS*)-6-éthyl-10,23-diméthyl-22-[4-(méthylamino)benzyl]-5,8,12,15,17,21,24-hepta-oxo-13-phényldocosahydro-12*H*-pyrido[2,1-*f*]pyrrolo[2,1-*h*][1,4,7,10,13,16]oxapentaazacyclononadécén-9-yl]-3-hydroxypyridine-2-carboxamide

efepristina

N-[(6*R*,9*S*,10*R*,13*S*,15*aS*,22*S*,24*aS*)-6-etildocosahidro-10,23-diméthil-22-[*p*-(metilamino)benzil]-5,8,12,15,17,21,24-hepta-oxo-13-fenil-12*H*-pirido[2,1-*f*]pirrolo[2,1-*h*][1,4,7,10,13,16]oxapentaazacyclononadecin-9-yl]-3-hidroxicolinamida

C₄₄H₅₂N₈O₁₀**elinafidum**

elinafide


N,N'-[triméthylènebis(iminoéthylène)]dinaphthalimide

élinafide

2,2'-[propane-1,3-diylbis(iminoéthylène)]bis[1*H*-benzo[*de*]isoquinoléine-1,3(2*H*)-dione]

elinafida

N,N'-[triméthilénobis(iminoéthileno)]dinaftalimida

C₃₁H₂₈N₄O₄

filaminastum


filaminast

3'-(cyclopentyloxy)-4'-methoxyacetophenone (*E*)-*O*-carbamoyloxime

filaminast

1-[3-(cyclopentyloxy)-4-méthoxyphényl]éthanone (*E*)-*O*-carbamoyloxime

filaminast

3'-(ciclopentiloxi)-4'-metoxiacetofenona (*E*)-*O*-carbamoiloximaC₁₅H₂₀N₂O₄**flibanserinum**


flibanserin

1-[2-[4-(α,α,α -trifluoro-*m*-tolyl)-1-piperazinyl]ethyl]-2-benzimidazolinone

flibansérine

1-[2-[4-[3-(trifluorométhyl)phényl]pipérazin-1-yl]éthyl]-1,3-dihydro-2*H*-benzimidazol-2-one

flibanserina

1-[2-[4-(α,α,α -trifluoro-*m*-tolil)-1-piperazinil]etil]-2-benzimidazolinonaC₂₀H₂₁F₃N₄O**fludarabinum**


fludarabine

9- β -D-arabinofuranosyl-2-fluoroadenine

fludarabine

9-(β -D-arabinofuranosyl)-2-fluoro-9*H*-purin-6-amine

fludarabina

9- β -D-arabinofuranosil-2-fluoroadeninaC₁₀H₁₂FN₅O₄

icopezilum



icopezil

3-[2-(1-benzyl-4-piperidyl)ethyl]-5,7-dihydro-6*H*-pyrrolo[3,2-*f*]-1,2-benzisoxazol-6-one

icopézil

3-[2-(1-benzylpipéridin-4-yl)éthyl]-5,7-dihydro-6*H*-pyrrolo[3,2-*f*]-1,2-benzisoxazol-6-one

icopezilo

3-[2-(1-bencil-4-piperidil)etil]-5,7-dihidro-6*H*-pirrolo[3,2-*f*]-1,2-benzisoxazol-6-onaC₂₃H₂₅N₃O₂**ioflupanum** (¹²³I)ioflupane (¹²³I)methyl 8-(3-fluoropropyl)-3β-(*p*-iodo-¹²³I-phenyl)-1α*H*,5α*H*-nortropane-2β-carboxylateioflupane (¹²³I)(1*R*,2*S*,3*S*,5*S*)-8-(3-fluoropropyl)-3-[4-[¹²³I]iodophényl]-8-azabicyclo[3.2.1]octane-2-carboxylate de méthyleioflupano (¹²³I)8-(3-fluoropropil)-3β-(*p*-iodo-¹²³I-fenil)-1α*H*,5α*H*-nortropano-2β-carboxilato de metiloC₁₈H₂₃F¹²³I_{NO}₂**ivabradinum**

ivabradine


3-[3-[[[(7*S*)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl]=methylamino]propyl]-1,3,4,5-tetrahydro-7,8-dimethoxy-2*H*-3-benzazepin-2-one

ivabradine

3-[3-[[[(7*S*)-3,4-diméthoxybicyclo[4.2.0]octa-1,3,5-trién-7-yl]méthyl]=méthylamino]propyl]-7,8-diméthoxy-1,3,4,5-tétrahydro-2*H*-3-benzazépin-2-one

ivabradina

3-[3-[[[(7*S*)-3,4-dimetoxibiciclo[4.2.0]octa-1,3,5-trien-7-il]metil]metilamino]=propil]-1,3,4,5-tetrahidro-7,8-dimetoxi-2*H*-3-benzazepin-2-ona

$C_{27}H_{36}N_2O_5$ **lagatidum**

lagatide

L-prolyl-L-valyl-L-threonyl-L-lysyl-L-prolyl-L-glutaminy-D-alaninamide

lagatide

L-prolyl-L-valyl-L-thréonyl-L-lysyl-L-prolyl-L-glutaminy-D-alaninamide

lagatida

L-prolii-L-valii-L-treoniil-L-lisil-L-prolii-L-glutaminil-D-alaninamida

 $C_{33}H_{58}N_{10}O_9$ H-Pro-Val-Thr-Lys-Pro-Gln-D-Ala-NH₂**landiololum**

landiolol


(-)-[(S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl p-[(S)-2-hydroxy-3-[[2-(4-morpholinocarboxamido)ethyl]amino]propoxy]hydrocinnamate

landiolol

(-)-3-[4-[(2S)-2-hydroxy-3-[[2-[(morpholin-4-ylcarbonyl)amino]éthyl]amino]=propoxy]phényl]propanoate de [(4S)-2,2-diméthyl-1,3-dioxolan-4-yl]méthyle

landiolol

p-[(S)-2-hidroxi-3-[[2-(4-morfolinocarboxamido)etil]amino]propoxi]=hidrocinnamato de (-)-[(S)-2,2-dimetil-1,3-dioxolan-4-il]metil

 $C_{25}H_{39}N_3O_8$ **lefradafibanum**

lefradafiban


(3S,5S)-5-[[[4'-(carboxyamidino)-4-biphenyl]oxy]methyl]-2-oxo-3-pyrrolidineacetic acid, dimethyl ester

léfradafiban

2-[(3S,5S)-5-[[[4'-[imino(méthoxycarbonyl)amino]méthyl]biphényl-4-yl]oxy]méthyl]-2-oxopyrrolidin-3-yl]acétate de méthyle

lefradafibán

éster dimetílico del ácido(3S,5S)-5-[[[4'-(carboxiamidino)-4-bifenilil]oxi]metil]-2-oxo-3-pirrolidinacético

C₂₃H₂₅N₃O₆**marimastatum**


marimastat

(2*S*,3*R*)-3-[[[(1*S*)-2,2-dimethyl-1-(methylcarbamoyl)propyl]carbamoyl]-2-hydroxy-5-methylhexanohydroxamic acid

marimastat

(2*R*,3*S*)-*N*¹-[[[(1*S*)-2,2-diméthyl-1-(méthylcarbamoyl)propyl]-*N*²,3-dihydroxy-2-(2-méthylpropyl)butanediamide

marimastat

ácido (2*S*,3*R*)-3-[[[(1*S*)-2,2-dimetil-1-(metilcarbamoil)propil]carbamoil]-2-hidroxi-5-metilhexanohidroxámicoC₁₅H₂₉N₃O₅**maxacalcitolum**


maxacalcitol

(+)-(5*Z*,7*E*,20*S*)-20-(3-hydroxy-3-methylbutoxy)-9,10-secopregna-5,7,10(19)-triene-1 α ,3 β -diol

maxacalcitol

(+)-(5*Z*,7*E*)-(20*S*)-20-(3-hydroxy-3-méthylbutoxy)-9,10-sécoprégna-5,7,10(19)-triène-1 α ,3 β -diol

maxacalcitol

(+)-(5*Z*,7*E*,20*S*)-20-(3-hidroxi-3-metilbutoxi)-9,10-secopregna-5,7,10(19)-trieno-1 α ,3 β -diolC₂₆H₄₂O₄

mazokalimum


mazokalim

ethyl 5-[(3*S*,4*R*)-4-[(1,6-dihydro-6-oxo-3-pyridazinyl)oxy]-3-hydroxy-2,2,3-trimethyl-6-chromanyl]-1*H*-tetrazole-1-butyrat

mazokalim

4-[5-[(3*S*,4*R*)-3-hydroxy-2,2,3-triméthyl-4-(6-oxo-1,6-dihydropyridazin-3-yloxy)-3,4-dihydro-2*H*-chromén-6-yl]-1*H*-tétrazol-1-yl]butanoate d'éthyle

mazokalim

5-[(3*S*,4*R*)-4-[(1,6-dihidro-6-oxo-3-piridazinil)oxi]-3-hidroxi-2,2,3-trimetil-6-cromanil]-1*H*-tetrazol-1-butirato de etiloC₂₃H₂₈N₆O₆**nifekalantum**


nifekalant

6-[[2-[(2-hydroxyethyl)[3-(*p*-nitrophenyl)propyl]amino]ethyl]amino]-1,3-dimethyluracil

nifékálant

6-[[2-[(2-hydroxyéthyl)[3-(4-nitrophényl)propyl]amino]éthyl]amino]-1,3-diméthylpyrimidin-2,4(1*H*,3*H*)-dione

nifekalant

6-[[2-[(2-hidroxietil)[3-(*p*-nitrofenil)propil]amino]etil]amino]-1,3-dimetiluraciloC₁₉H₂₇N₅O₅**nolpantii besilas**

nolpantium besilate


1-[2-[(*S*)-3-(3,4-dichlorophenyl)-1-[(*m*-isopropoxyphenyl)acetyl]-3-piperidyl]ethyl-4-phenylquinuclidinium benzenesulfonate

bésilate de nolpantium

benzènesulfonate de 1-[2-[(3*S*)-3-(3,4-dichlorophényl)-1-[2-[3-(1-méthyléthoxy)phényl]acétyl]pipéridin-3-yl]éthyl]-4-phényl-1-azoniabicyclo[2.2.2]octane

besilato de nolpantio

bencenosulfonato de 1-[2-[(*S*)-3-(3,4-diclorofenil)-1-[(*m*-isoproxifenil)acetil]-3-piperidil]etil]-4-fenilquinuclidinio

C₄₃H₅₀Cl₂N₂O₅S**orbofibanum**

orbofiban


N-[[*(3S)*-1-(*p*-amidinophenyl)-2-oxo-3-pyrrolidiny]carbamoil]-
β-alanine, ethyl ester

orbofiban

3-[3-[[*(3S)*-1-(4-carbamimidoylphényl)-2-oxopyrrolidin-3-yl]uréido]propanoate
d'éthyle

orbofiban

éster etílico de la *N*-[[*(3S)*-1-(*p*-amidinofenil)-2-oxo-3-pirrolidinil]carbamoil]-
β-alanina

C₁₇H₂₃N₅O₄**pranazepidum**

pranazepide


(-)-*N*-[*(S)*-1-(*o*-fluorophenyl)-3,4,6,7-tetrahydro-4-oxopyrrolo=
[3,2,1-*jk*][1,4]benzodiazepin-3-yl]indole-2-carboxamide

pranazépide

(-)-*N*-[[*(3S)*-1-(2-fluorophényl)-4-oxo-3,4,6,7-tétrahydropyrrolo=
[3,2,1-*jk*][1,4]benzodiazépin-3-yl]-1*H*-indole-2-carboxamide

pranazepida

(-)-*N*-[[*(S)*-1-(*o*-fluorofenil)-3,4,6,7-tetrahidro-4-oxopirrolo=
[3,2,1-*jk*][1,4]benzodiazepin-3-il]indol-2-carboxamida

C₂₆H₁₉FN₄O₂

rizatriptanum


rizatriptan

3-[2-(dimethylamino)ethyl]-5-(1*H*-1,2,4-triazol-1-ylmethyl)indole

rizatriptan

N,N-diméthyl-2-[5-[(1*H*-1,2,4-triazol-1-yl)méthyl]-1*H*-indol-3-yl]éthanamine

rizatriptán

3-[2-(dimetilamino)etil]-5-(1*H*-1,2,4-triazol-1-ilmetil)indolC₁₅H₁₉N₅**saredutantum**


saredutant

N-[(*S*)-β-2-(4-acetamido-4-phenylpiperidino)ethyl]-3,4-dichlorophenethyl]-*N*-methylbenzamide

sarédutant

N-[(2*S*)-4-[4-(acétylamino)-4-phénylpipéridin-1-yl]-2-(3,4-dichlorophényl)butyl]-*N*-méthylbenzamide

saredutant

N-[(*S*)-β-2-(4-acetamido-4-fenilpiperidino)etil]-3,4-diclorofenetil]-*N*-metilbenzamidaC₃₁H₃₅Cl₂N₃O₂**sitafloxacinum**

sitafloxacin


(-)-7-[(7*S*)-7-amino-5-azaspiro[2.4]hept-5-yl]-8-chloro-6-fluoro-1-[(1*R*,2*S*)-2-fluorocyclopropyl]-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid

sitafloxacine

acide (-)-7-[(7*S*)-7-amino-5-azaspiro[2.4]hept-5-yl]-8-chloro-6-fluoro-1-[(1*R*,2*S*)-2-fluorocyclopropyl]-4-oxo-1,4-dihydroquinoléin-3-carboxylique

sitafloxacino

ácido (-)-7-[(7*S*)-7-amino-5-azaspiro[2.4]hept-5-il]-8-cloro-6-fluoro-1-[(1*R*,2*S*)-2-fluorociclopropil]-1,4-dihidro-4-oxo-3-quinolinacarboxílico

C₁₉H₁₈ClF₂N₃O₃**sulesomabum**

sulesomab

immunoglobulin G 1 (mouse monoclonal IMMU-MN3 Fab' fragment γ -chain anti-human NCA-90 granulocyte cell antigen), disulfide with mouse monoclonal IMMU-MN3 light chain

sulésomab

immunoglobuline G 1 (chaîne γ du fragment Fab' de l'anticorps monoclonal de souris IMMU-MN3 anti-antigène de granulocyte humain NCA-90), disulfure avec la chaîne légère de l'anticorps monoclonal de souris IMMU-MN3

sulesomab

immunoglobulina G 1 (cadena γ del fragmento Fab' del anticuerpo monoclonal de ratón IMMU-MN3 anti-antígeno de granulocito humano NCA-90), disulfuro con la cadena ligera del anticuerpo monoclonal de ratón IMMU-MN3

taltirelinum

taltirelin


(-)-N-[[[(S)-hexahydro-1-methyl-2,6-dioxo-4-pyrimidinyl]carbonyl]-L-histidyl-L-prolinamide

taltiréline

(-)-(2S)-1-[(2S)-3-(1H-imidazol-4-yl)-2-[[[(4S)-1-méthyl-2,6-dioxohexahydro-pyrimidin-4-yl]carbonyl]amino]propanoyl]pyrrolidine-2-carboxamide

taltirelina

(-)-N-[[[(S)-hexahidro-1-metil-2,6-dioxo-4-pirimidinil]carbonil]-L-histidil-L-prolinamida

C₁₇H₂₃N₇O₅**talviralinum**


talviraline

isopropyl (2S)-3,4-dihydro-7-methoxy-2-[(methylthio)methyl]-3-thioxo-1(2H)-quinoxalinecarboxylate

talviraline

(2S)-7-méthoxy-2-[(méthylsulfanyl)méthyl]-3-thioxo-3,4-dihydroquinoxaline-1(2H)-carboxylate de 1-méthyléthyle

talviralina

(2*S*)-3,4-dihidro-7-metoxi-2-[(metiltio)metil]-3-tioxo-1(2*H*)-quinoxalinacarboxilato de 1-metiletiloC₁₅H₂₀N₂O₃S₂

technetium (^{99m}Tc) pintumomabum
 technetium (^{99m}Tc) pintumomab

immunoglobulin G 1 (mouse monoclonal 170 γ-chain anti-human adenocarcinoma antigen), disulfide with mouse monoclonal 170 κ-chain, dimer, [^{99m}Tc]technetium salt

technétium (^{99m}Tc) pintumomab

sel de [^{99m}Tc]technétium de l'immunoglobuline G 1 (chaîne γ de l'anticorps monoclonal de souris 170 anti-antigène associé à l'adénocarcinome humain), dimère du disulfure avec la chaîne κ de l'anticorps monoclonal de souris 170

technetium (^{99m}Tc) pintumomab

sal de [^{99m}Tc]technetium del inmunoglobulina G 1 (cadena γ del anticuerpo monoclonal de ratón 170 anti-antígeno asociado al adenocarcinoma humano), dímero del disulfuro con la cadena κ del anticuerpo monoclonal de ratón 170

terbogrelum


terbogrel

(5*E*)-6-[*m*-(3-*tert*-butyl-2-cyanoguanidino)phenyl]-6-(3-pyridyl)-5-hexenoic acid

terbogrel

acide (5*E*)-6-[3-[2-cyano-3-(1,1-diméthyléthyl)guanidino]phényl]-6-(pyrid-3-yl)hex-5-énoïque

terbogrel


ácido (5*E*)-6-[*m*-(3-*tert*-butil-2-cianoguanidino)fenil]-6-(3-piridil)-5-hexenóicoC₂₃H₂₇N₅O₂

tresperimusum

tresperimus


[4-[(3-aminopropyl)amino]butyl]carbamic acid, ester with *N*-(6-guanidino)hexylglycolamide

trespérimus	[4-[(3-aminopropyl)amino]butyl]carbamate de 2-[(6-guanidinohexyl)amino]-2-oxoéthyle
tresperimus	[4-[(3-aminopropil)amino]butil]carbamato de [(6-guanidinohexil)carbamoil]=metilo C ₁₇ H ₃₇ N ₇ O ₃



vinfluninum	
vinflunine	4'-deoxy-20',20'-difluoro-8'-norvincaléukoblastine
vinflunine	20',20'-difluoro-4'-désoxy-8'-norvincaléucoblastine
vinflunina	4'-desoxi-20',20'-difluoro-8'-norvincaléucoblastina C ₄₅ H ₅₄ F ₂ N ₄ O ₈

zanamivirum	
zanamivir	5-acetamido-2,6-anhydro-3,4,5-trideoxy-4-guanidino-D-glycero-D-galacto-non-2-enonic acid
zanamivir	acide (4 <i>S</i> ,5 <i>R</i> ,6 <i>R</i>)-5-(acétylamino)-4-guanidino-6-[(1 <i>R</i> ,2 <i>R</i>)-1,2,3-trihydroxypropyl]-5,6-dihydro-4 <i>H</i> -pyrane-2-carboxylique
zanamivir	ácido 5-acetamido-2,6-anhidro-3,4,5-tridesoxi-4-guanidino-D-glicero-D-galacto-non-2-enónico C ₁₂ H ₂₀ N ₄ O ₇



Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in uneven numbers of proposed INN lists only.

Les textes de la *Procédure à suivre en vue de choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les listes impaires des DCI proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en los números impares de las listas de DCI propuestas.